NDA 021345 · Mylan Ireland LTD
Arixtra
Fondaparinux Sodium · Subcutaneous
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Dec 23, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Dec 7, 2001
Approved uses
6
Original approval plus efficacy supplements
Registered trials
64
29 Phase 3, 4 recruiting
FAERS reports
8,080
7,120 serious, 1,444 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH), heparinoids, or fondaparinux sodium and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity or spinal surgery • Optimal timing between the administration of fondaparinux sodium and neuraxial procedures...
What it is approved for
From the label in effect Dec 15, 2024.
Fondaparinux sodium injection is a Factor Xa inhibitor (anticoagulant) indicated for: • Prophylaxis of deep vein thrombosis (DVT) in adult patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. ( 1.1 ) • Treatment of DVT or acute pulmonary embolism (PE) in adult patients when administered in conjunction with warfarin sodium. ( 1.2 , 1.3 ) • Treatment of venous thromboembolism (VTE) in pediatric patients aged 1 year or older weighing at least 10 kg. ( 1.4 ) 1.1 Prophylaxis of Deep Vein Thrombosis in Adult Patients Fondaparinux sodium injection is indicated for the prophylaxis of deep vein thrombosis (DVT) in adults, which may lead to pulmonary embolism (PE): • in patients undergoing hip fracture surgery, including extended prophylaxis; • in patients undergoing hip replacement surgery; • in patients undergoing knee replacement surgery; • in patients undergoing abdominal surgery who are at risk for thromboembolic complications. 1.2 Treatment of Acute Deep Vein Thrombosis in Adult Patients Fondaparinux sodium injection is indicated for the treatment of acute deep vein thrombosis in adults when administered in conjunction with warfarin sodium. 1.3 Treatment of Acute Pulmonary Embolism in Adult Patients Fondaparinux sodium injection is indicated for the treatment of acute pulmonary embolism in adults when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. 1.4 Treatment of Venous Thromboembolism in Pediatric Patients Fondaparinux sodium injection is indicated for the treatment of venous thromboembolism (VTE) in pediatric patients aged 1 year or older weighing at least 10 kg .
Mechanism: The antithrombotic activity of fondaparinux sodium is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa. By selectively binding to ATIII, fondaparinux sodium potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits thrombin formation and thrombus development. Fondaparinux sodium does not inactivate thrombin (activated Factor II) and has no known effect on platelet function. At the recommended dose, fondaparinux sodium does not affect fibrinolytic...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 23, 2024 Supplement 52 · Efficacy LabelLetter
- May 26, 2005 Supplement 10 · Efficacy LabelLetter
- May 28, 2004 Supplement 4 · Efficacy LabelLetter
- May 28, 2004 Supplement 5 · Efficacy LetterLabel
- Jun 17, 2003 Supplement 2 · Efficacy · priority review LabelLetter
- Dec 7, 2001 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewLetterLabel
4 products under this application
- ARIXTRA · FONDAPARINUX SODIUM 7.5MG/0.6ML (7.5MG/0.6ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP
- ARIXTRA · FONDAPARINUX SODIUM 2.5MG/0.5ML (2.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP
- ARIXTRA · FONDAPARINUX SODIUM 10MG/0.8ML (10MG/0.8ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP
- ARIXTRA · FONDAPARINUX SODIUM 5MG/0.4ML (5MG/0.4ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Fondaparinux" as an intervention, any sponsor and status, largest first.
- Michelangelo - Oasis 5Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00139815 · 20,078 participants · Start Apr 2003 · Primary completion Dec 2005
Drug: Fondaparinux; enoxaparin · For: Thromboembolism
- OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial InfarctionPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00064428 · 12,092 participants · Start Aug 2003 · Primary completion Feb 2006
Drug: fondaparinux - UFH not indicated; Fondaparinux - UFH indicated and 1 more · For: Thromboembolism
- Thromboprophylaxis in Lower Limb ImmobilisationPivotal-lookingRecruiting
Queen Mary University of LondonAcademic, hospital or other
NCT06370273 · 10,044 participants (planned) · Start Nov 12, 2024 · Primary completion Aug 31, 2028
Drug: Rivaroxaban; Apixaban and 4 more · For: Thrombosis; Injury Leg
Sites: Carshalton, United Kingdom; Hull, United Kingdom; London, United Kingdom · 5 sites in all
- Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial InfarctionPivotal-lookingRecruiting
University of AarhusAcademic, hospital or other
NCT06710184 · 5,076 participants (planned) · Start May 1, 2025 · Primary completion Jan 1, 2029
Drug: Aspirin; Fondaparinux Sodium · For: NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI); Acute Myocardial Infarction (AMI)
Sites: Herning, Denmark; Horsens, Denmark; Viborg, Denmark · 10 sites in all
- Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00790907 · 3,235 participants · Start Feb 2009 · Primary completion May 2010
Drug: fondaparinux background and standard dose UFH; Fondaparinux background and low dose heparin and 1 more · For: Acute Coronary Syndrome
Sites: Ocala, Florida; Albuquerque, New Mexico; Syracuse, New York · 203 sites in all
- Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00443053 · 3,002 participants · Start Mar 2007 · Primary completion Jul 2009
Drug: Fondaparinux 2.5mg or placebo · For: Thrombosis, Venous
Sites: Sofia, Bulgaria; Brno, Czechia; Olomouc, Czechia · 227 sites in all
- A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing SurgeryPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00843492 · 1,351 participants · Start Dec 2008 · Primary completion Jan 2010
Drug: Fondaparinux sodium; Nadroparin · For: Thrombosis, Venous
Sites: Agen, France; Angers, France; Antony, France · 122 sites in all
GlaxoSmithKlineGSK (GSK)
NCT00038961 · 1,309 participants · Start Nov 2001 · Primary completion Oct 2004
Drug: fondaparinux sodium · For: Thromboembolism
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- anaemia610
- haematoma561
- pulmonary embolism449
- off label use372
- haemorrhage353
- haemoglobin decreased339
- death297
- deep vein thrombosis294
- dyspnoea272
- thrombocytopenia264
- drug ineffective259
- pyrexia240
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 138 |
| 2005 | 85 |
| 2006 | 193 |
| 2007 | 510 |
| 2008 | 608 |
| 2009 | 748 |
| 2010 | 772 |
| 2011 | 745 |
| 2012 | 745 |
| 2013 | 676 |
| 2014 | 561 |
| 2015 | 274 |
| 2016 | 187 |
| 2017 | 215 |
| 2018 | 293 |
| 2019 | 203 |
| 2020 | 208 |
| 2021 | 178 |
| 2022 | 172 |
| 2023 | 171 |
| 2024 | 156 |
| 2025 | 145 |
| 2026 | 97 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Arixtra (Fondaparinux Sodium)
2024 spending
$211K
Beneficiaries
n/a
46 claims
Per beneficiary
n/a
$181.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $632,611 |
| 2021 | $431,028 |
| 2022 | $332,756 |
| 2023 | $219,451 |
| 2024 | $211,072 |
Part B: Arixtra* (Fondaparinux Sodium*) · HCPCS J1652
2024 spending
$2K
Beneficiaries
28
147 claims
Per beneficiary
$76
2024 ASP limit $1.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $10,985 |
| 2021 | $7,531 |
| 2022 | $4,918 |
| 2023 | $2,092 |
| 2024 | $2,130 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 3-Defining antithrombotic protocols.
Blais MC, Bianco D, Goggs R, et al. · J Vet Emerg Crit Care (San Antonio) 2019 · Consensus Statement, Practice Guideline
- Dosage of Anticoagulants in Obesity: Recommendations Based on a Systematic Review.
Abildgaard A, Madsen SA, Hvas AM · Semin Thromb Hemost 2020 · Systematic Review
- Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
Schrag D, Uno H, Rosovsky R, et al. · JAMA 2023 · Comparative Study, Equivalence Trial
- Fondaparinux-associated heparin-induced thrombocytopenia.
Bhatt VR, Aryal MR, Shrestha R, et al. · Eur J Haematol 2013 · Meta-Analysis
- Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
Beyer-Westendorf J, Schellong SM, Gerlach H, et al. · Lancet Haematol 2017 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and Safety of DOACs for the Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis.
Boccatonda A, Brighenti A, Simion C, et al. · Thromb Haemost 2026 · Systematic Review, Meta-Analysis
Sponsor: Mylan Ireland LTD
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.